Medical Condition News

RSS

New global map shows distribution of sickle cell gene

At a global scale, the sickle cell gene is most commonly found in areas with historically high levels of malaria, adding geographical support to the hypothesis that the gene, whilst potentially deadly, avoids disappearing through natural selection by providing protection against malaria.

3 Nov 2010

Curemark awarded QTDP grant to advance development of CM-AT for autism

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.

3 Nov 2010

Celsion receives $244,000 grant under QTDP program

Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).

3 Nov 2010

Synergenz awarded $94,836 research grant under federal QTDP program

Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

Study suggests heredity may play a role in determining infant's susceptibility to AOP

A potentially life-threatening challenge characterized by pauses in breathing that can last for more than 20 seconds, apnea of prematurity (AOP) affects more than 50 percent of premature infants and is almost universal in the smallest of preemies. Caused in part by an underdeveloped central nervous system that can't adequately regulate breathing outside of the womb, especially during sleep, AOP is not yet fully understood by scientists and remains a grave concern among neonatologists and parents alike.

3 Nov 2010

Study: Illnesses and injuries that restrict activity linked to worsening functional ability in older adults

A study by Yale School of Medicine researchers reveals that the illnesses and injuries that can restrict the activity of older adults or land them in the hospital are linked to worsening functional ability, especially among those who are physically frail. The report appears in JAMA's November 3 theme issue on aging.

3 Nov 2010

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010

UIC awarded $12M to study acquired and familial causes of heart failure

Researchers at the University of Illinois at Chicago have been awarded more than $12 million by the National Heart, Lung, and Blood Institute to investigate both the acquired and familial causes of heart failure -- with the aim of identifying markers for diagnosis and targets for cures.

3 Nov 2010

Neoprobe receives $244,479 grant under QTDP program

Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has been awarded a grant of $244,479 under the qualifying therapeutic discovery project program established under Section 48D of the Internal Revenue Code.

3 Nov 2010

BioCryst receives $1.1 million in grants under QTDP program

BioCryst Pharmaceuticals, Inc. today announced that the Company had been awarded $1.1 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company's clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Roux-en-Y gastric bypass surgery effective for morbid obesity

Gastric bypass surgery decreases the preference for sweet-tasting substances in obese rats, a study finding that could help in developing safer treatments for the morbidly obese, according to Penn State College of Medicine researchers.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Drinking beet juice increases blood flow to the brain

Researchers for the first time have shown that drinking beet juice can increase blood flow to the brain in older adults - a finding that could hold great potential for combating the progression of dementia.

3 Nov 2010

Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program

Enzon Pharmaceuticals, Inc. today announced that it has been awarded $1.2 million in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

3 Nov 2010

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen, Inc. a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.

3 Nov 2010

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

3 Nov 2010

Medical Condition News

New global map shows distribution of sickle cell gene

Curemark awarded QTDP grant to advance development of CM-AT for autism

Celsion receives $244,000 grant under QTDP program

Synergenz awarded $94,836 research grant under federal QTDP program

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Study suggests heredity may play a role in determining infant's susceptibility to AOP

Study: Illnesses and injuries that restrict activity linked to worsening functional ability in older adults

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

UIC awarded $12M to study acquired and familial causes of heart failure

Neoprobe receives $244,479 grant under QTDP program

BioCryst receives $1.1 million in grants under QTDP program

Immunomedics product candidates, technologies receive recognition from QTDP program

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Roux-en-Y gastric bypass surgery effective for morbid obesity

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Drinking beet juice increases blood flow to the brain

Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News